National Institutes of Health: Fatty Liver trials

The registry lists 26 Fatty Liver studies with National Institutes of Health as lead sponsor. 3 are open to participants now and 13 have results posted.

Phase 1 4Phase 2 14Phase 3 3Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy DrinkersRecruitingNCT04781322Phase 1
• Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)RecruitingNCT03884075Phase 2
• Early Tracking of Childhood Health Determinants (ETCHED) StudyRecruitingNCT03481829
• Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)CompletedNCT04216589Phase 2Results posted
• Losartan for the Treatment of Pediatric NAFLDTerminatedNCT03467217Phase 2Results posted
• Cardiometabolic Effects of Eplerenone in HIV InfectionTerminatedNCT02629094Phase 2Results posted
• Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin ECompletedNCT01792115Phase 2Results posted
• Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in ChildrenCompletedNCT01529268Phase 2/3Results posted
• The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)CompletedNCT01265498Phase 2Results posted
• Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C InfectionsTerminatedNCT00742326Phase 4Results posted
• Pioglitazone to Treat Fatty Liver in People With HIV InfectionCompletedNCT00441272Phase 2Results posted
• Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty LiverCompletedNCT00323414Phase 2Results posted
• Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)CompletedNCT00063635Phase 3Results posted
• Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)CompletedNCT00063622Phase 3Results posted
• Treating Nonalcoholic Steatohepatitis (NASH) With MetforminCompletedNCT00063232Phase 2Results posted
• Treating Nonalcoholic Steatohepatitis With PioglitazoneCompletedNCT00062764Phase 2Results posted
• Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver DiseaseCompletedNCT02520609
• Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)CompletedNCT02363309
• Genetic Studies of Non-Alcoholic Fatty Liver DiseaseTerminatedNCT01629095
• Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese WomenCompletedNCT00862433Phase 1
• MRI to Measure Liver Fat ContentCompletedNCT00594412Not applicable
• Phase I Trial of Silymarin for Chronic Liver DiseasesCompletedNCT00389376Phase 1
• Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral TherapyCompletedNCT00326482
• Weight Management in Nonalcoholic SteatohepatitisCompletedNCT00266019Phase 2
• The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in DiabeticsTerminatedNCT00068094Phase 1/2
• Treatment of Nonalcoholic Steatohepatitis With PioglitazoneCompletedNCT00013598Phase 2